The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Mechanisms of Botulinum Toxin Type A Action on Pain
Open accessAbstract
Already a well-established treatment for different autonomic and movement disorders, the use of botulinum toxin type A (BoNT/A) in pain conditions is now continuously expanding. Currently, the only approved use of BoNT/A in relation to pain is the treatment of chronic migraines. However, controlled clinical studies show promising results in neuropathic and other chronic pain disorders. In comparison with other conventional and non-conventional analgesic drugs, the greatest advantages of BoNT/A use are its sustained effect after a single application and its safety. Its efficacy in certain therapy-resistant pain conditions is of special importance. Novel results in recent years has led to a better understanding of its actions, although further experimental and clinical research is warranted. Here, we summarize the effects contributing to these advantageous properties of BoNT/A in pain therapy, specific actions along the nociceptive pathway, consequences of its central activities, the molecular mechanisms of actions in neurons, and general pharmacokinetic parameters.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980 · cited 1×
“The pharmacotherapeutic options for the treatment of chronic migraine and neuropathic pain are very limited, with certain antiepileptics and antidepressants [121,122], and the development of analgesics with novel mechanisms of action has proven to be extremely challenging [123].”
BackgroundBotulinum Toxin as a Biological Weapon: Medical and Public Health Management
Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Hauer, J., Layton, M., et al. (2001) · JAMA · doi:10.1001/jama.285.8.1059 · Cited by 1,814
Dodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H., & Brin, M. F. (2010) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2010.01678.x · Cited by 994
DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS
Tsui, J. C., Jon Stoessl, A., Eisen, A., Calne, S., & Calne, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92070-2 · Cited by 810
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology
Pirazzini, M., Rossetto, O., Eleopra, R., & Montecucco, C. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012658 · Cited by 768
Subcutaneous administration of botulinum toxin A reduces formalin-induced pain
Cui, M., Khanijou, S., Rubino, J., & Aoki, K. R. (2004) · Pain · doi:10.1016/j.pain.2003.10.008 · Cited by 676
Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain
Ranoux, D., Attal, N., Morain, F., & Bouhassira, D. (2008) · Annals of Neurology · doi:10.1002/ana.21427 · Cited by 459
Adherence to oral migraine-preventive medications among patients with chronic migraine
Hepp, Z., Dodick, D. W., Varon, S. F., Gillard, P., Hansen, R. N., & Devine, E. B. (2015) · Cephalalgia · doi:10.1177/0333102414547138 · Cited by 433
Regulated Exocytosis Contributes to Protein Kinase C Potentiation of Vanilloid Receptor Activity
Morenilla-Palao, C., Planells-Cases, R., García-Sanz, N., & Ferrer-Montiel, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311515200 · Cited by 425
Hepp, Z., Dodick, D. W., Varon, S. F., Chia, J., Matthew, N., Gillard, P., Hansen, R. N., & Devine, E. B. (2017) · Cephalalgia · doi:10.1177/0333102416678382 · Cited by 359
Metadata
- Authors
- Matak, I., Bölcskei, K., Bach-Rojecky, L., & Helyes, Z.
- Venue
- Toxins
- Publisher
- MDPI AG
- Published
- 2019-08-05
- Volume
- 11
- Issue
- 8
- Pages
- 459
- ISSN
- 2072-6651 (ISSN-L)
- OpenAlex
- W2965226820
- Cited by
- 267
- References
- 91
- FWCI
- 15.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of Botulinum Toxin Type A Action on Pain. https://app.cochat.ai/papers/10.3390/toxins11080459
- The paper
- Matak, I., Bölcskei, K., Bach-Rojecky, L., & Helyes, Z. (2019). Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins. https://doi.org/10.3390/toxins11080459
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.